As a scientist and internationally acknowledged expert he is specialized in the pathology of the retinal pigment epithelium, a key cell layer for pathogenic events in AMD. The purpose of his unit is the discovery of candidates for ophthalmological drug development and also the support of pharmaceutical entities in toxicological and efficacy studies with respect to events in the eye.

Dr. Schraermeyer also heads the Section of Experimental Vitroretinal Surgery at the Centre for Ophthalmology, University Eye Hospital in Tübingen.

As a co-founder of the biotechnology companies Cevec in 2003, and katairo in 2011 he has gathered first hand industrial experience.

Dr. Schraermeyer holds a degree in cellular biology and a PhD from the University of Düsseldorf.

As a scientist and internationally acknowledged expert he is specialized in the pathology of the retinal pigment epithelium, a key cell layer for pathogenic events in AMD. The purpose of his unit is the discovery of candidates for ophthalmological drug development and also the support of pharmaceutical entities in toxicological and efficacy studies with respect to events in the eye.

Dr. Schraermeyer also heads the Section of Experimental Vitroretinal Surgery at the Centre for Ophthalmology, University Eye Hospital in Tübingen.

As a co-founder of the biotechnology companies Cevec in 2003, and katairo in 2011 he has gathered first hand industrial experience.

Dr. Schraermeyer holds a degree in cellular biology and a PhD from the University of Düsseldorf.